WO2000015207A3 - Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) - Google Patents

Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) Download PDF

Info

Publication number
WO2000015207A3
WO2000015207A3 PCT/IB1999/001547 IB9901547W WO0015207A3 WO 2000015207 A3 WO2000015207 A3 WO 2000015207A3 IB 9901547 W IB9901547 W IB 9901547W WO 0015207 A3 WO0015207 A3 WO 0015207A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibacterial agent
treatment
inhibitor
elastine
inflammation
Prior art date
Application number
PCT/IB1999/001547
Other languages
French (fr)
Other versions
WO2000015207A2 (en
WO2000015207B1 (en
Inventor
Samarendra N Maiti
O A Phillips
Sameeh Salama
Ronald G Micetich
Original Assignee
Naeja Pharmaceutical Inc
Samarendra N Maiti
O A Phillips
Sameeh Salama
Ronald G Micetich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naeja Pharmaceutical Inc, Samarendra N Maiti, O A Phillips, Sameeh Salama, Ronald G Micetich filed Critical Naeja Pharmaceutical Inc
Priority to AU55282/99A priority Critical patent/AU5528299A/en
Publication of WO2000015207A2 publication Critical patent/WO2000015207A2/en
Publication of WO2000015207A3 publication Critical patent/WO2000015207A3/en
Publication of WO2000015207B1 publication Critical patent/WO2000015207B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method of treatment is provided to treat inflammation associated with human neutrophil elastase mediated disorders, particularly diseases of respiratory system or oral cavity. The method comprises a combined therapy of administering an elastase inhibitor(s) with an antibacterial agent(s), directed against pathogenic bacteria associated with disease of the respiratory system and oral cavity. A pharmaceutical composition comprising at least one antibacterial agent, and at least one elastase inhibitor is provided, preferably in aerosolized form, as well as a kit containing the respective components in separate packages.
PCT/IB1999/001547 1998-09-15 1999-09-15 Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) WO2000015207A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55282/99A AU5528299A (en) 1998-09-15 1999-09-15 Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10038698P 1998-09-15 1998-09-15
US60/100,386 1998-09-15

Publications (3)

Publication Number Publication Date
WO2000015207A2 WO2000015207A2 (en) 2000-03-23
WO2000015207A3 true WO2000015207A3 (en) 2000-05-25
WO2000015207B1 WO2000015207B1 (en) 2000-07-13

Family

ID=22279479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001547 WO2000015207A2 (en) 1998-09-15 1999-09-15 Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)

Country Status (2)

Country Link
AU (1) AU5528299A (en)
WO (1) WO2000015207A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1259260A1 (en) * 2000-01-06 2002-11-27 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
US6552082B2 (en) * 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
JP2004529095A (en) * 2001-02-13 2004-09-24 イントラバイオティクス ファーマシューティカルズ，インコーポレイテッド Prevention of ventilator-associated pneumonia by oral administration of antibacterial IB-367 peptide
DK1594500T3 (en) * 2003-02-10 2011-01-24 Bayer Schering Pharma Ag Treatment of bacterial diseases of the respiratory organs by local application of fluoroquinolones
DE10350409A1 (en) * 2003-10-28 2005-05-25 Bayer Healthcare Ag Method employing quinolones and related substances for treatment and prophylaxis of genetic diseases causing local mutations and comparable defects in higher organisms, including human beings
CN108570418A (en) * 2018-04-08 2018-09-25 山东农业大学 A kind of aspergillus fumigatus agar beads and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564317A (en) * 1976-06-25 1980-04-10 Roche Products Ltd Dipeptide derivatives
US4613587A (en) * 1983-09-23 1986-09-23 Yeda Research And Development Co. Ltd. Ophthalmic preparations
US5439904A (en) * 1993-12-07 1995-08-08 Synphar Laboratories, Inc. 2-spiro(2'-spirocycloalkyl)cyclopropyl cephalosporin sulfones as antiinflammatory and antigenerative agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564317A (en) * 1976-06-25 1980-04-10 Roche Products Ltd Dipeptide derivatives
US4613587A (en) * 1983-09-23 1986-09-23 Yeda Research And Development Co. Ltd. Ophthalmic preparations
US5439904A (en) * 1993-12-07 1995-08-08 Synphar Laboratories, Inc. 2-spiro(2'-spirocycloalkyl)cyclopropyl cephalosporin sulfones as antiinflammatory and antigenerative agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FURUNO, TAKASHI ET AL: "The role of neutrophil elastase in human pulmonary artery endothelial cel injury", INT. ARCH. ALLERGY IMMUNOL. (1997), 112(3), 262-269, 1997, XP000879176 *

Also Published As

Publication number Publication date
WO2000015207A2 (en) 2000-03-23
AU5528299A (en) 2000-04-03
WO2000015207B1 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
CA2191101A1 (en) Materials and methods for treatment of plaquing diseases
HUP0301815A3 (en) Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment
CA2289717A1 (en) Novel therapy for constipation
BG101118A (en) Therapeutical compounds
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
AU1581692A (en) Inhibitors of human neutrophil elastase and human cathepsin g
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
PL320687A1 (en) Use of incense for treating alzheimer disease
AU3092397A (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
WO2000008007A3 (en) Cyclopentabenzofuran derivatives and their use
WO2000015207A3 (en) Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
DE60031016D1 (en) Use of antiseptics for the preparation of medicaments for the prophylaxis and treatment of inflammation in the interior of the human body
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
AU2003290015A1 (en) Mastitis treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 09786372

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase